Amgen Inc.

William H Buckner

John Laird Buchanan

Craig E Masse

David Craig McGowan

Ning Xi

Matthew W Martin

Andrew Stewart Tasker

Joseph L Kim

Jean-Christophe P Harmange

Vinod Francis Patel

Matthew M Weiss

Frank Kayser

Brian Lewis Hodous

Shon Booker

Xiaotian Zhu

Yuan Cheng

Shimin Xu

Steven F Bellon

Lucian V DiPietro

Daniel La

Russell Graceffa

Tae-Seong Kim

Joseph J Nunes

Julie Germain

Erin F DiMauro

Stuart C Chaffee

Deborah Choquette

Michele Potashman

Gregory J Habgood

George Borg

Douglas A Whittington

Gang Liu

Brian K Albrecht

Jean E Bemis

Anthony B Reed

Robert Michael Rzasa

Ryan D White

Victor J Cee

Liping H Pettus

Dawei Zhang

David John Kopecky

Xiaolin Hao

Rajiv Sharma

Mario G Cardozo

Christopher Neil Farthing

James Richard Falsey

Sarah Lively

Paul A Tempest

Adrian Leonard Smith

Philip R Olivieri

Nick A Paras

Bradley J Herberich

Jiasheng Fu

Jinqian Liu

Holly L Deak

Guo-Qiang Cao

Partha P Chakrabarti

Xian Yun Jiao

Stephen J Shuttleworth

Alexander David Frenkel

Simon A Burkitt

Teresa L Marshall

Martin J Harrison

Maya C Thaman

Susan A Tomlinson

Kelvin Sham

David C Mcgowan

Susan Ann Tomlinson

Frenel F Demorin

Guo-Giang Cao

John L Buchanan

Erin F Dimauro

Stephanie D Geuns-Meyer

Stephanie D Geuns-meyer

Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Compounds and methods of use

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

Furanopyrimidines

The present invention relates to compounds of Formula I or a stereomer, a tautomer, a solvate, a pharmaceutically acceptable salt, or a prodrug thereof, pharmaceutical formulations containing the compounds, methods of treatments using the compounds, for example, protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders and methods of preparing medicaments comprising the compounds.

Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors

Growing community of inventors

Kittery, ME, United States of America

William H Buckner